-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Initiates Coverage On Mentari Therapeutics with Buy Rating, Announces Price Target of $30

Benzinga·11/10/2026 14:28:02
Jefferies analyst Andrew Tsai initiates coverage on Mentari Therapeutics (NASDAQ:MTRI) with a Buy rating and announces Price Target of $30.